Nexalin Technology, Inc. Common Stock
NXLNexalin Technology, Inc. (NXL) is a healthcare company that develops and markets neurostimulation devices aimed at treating neurological and psychiatric conditions, such as anxiety, depression, and chronic pain. The company's non-invasive, transcranial electrical stimulation devices are designed to provide therapeutic relief through electrical impulses delivered to specific areas of the brain.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 16, 2007 | $0.31 | 2007-03-23 | 2007-03-27 |
| January 16, 2007 | $0.31 | 2007-01-03 | 2007-01-05 |
| October 16, 2006 | $0.31 | 2006-09-28 | 2006-10-02 |
| July 17, 2006 | $0.31 | 2006-06-29 | 2006-07-03 |
| April 17, 2006 | $0.31 | 2006-03-30 | 2006-04-03 |
Dividends Summary
- Consistent Payer: Nexalin Technology, Inc. Common Stock has rewarded shareholders with 14 dividend payments over the past 3 years.
- Total Returned Value: Investors who held NXL shares during this period received a total of $7.66 per share in dividend income.
- Latest Payout: The most recent dividend of $0.31/share was paid 7033 days ago, on April 16, 2007.
- Yield & Schedule: NXL currently pays dividends quarterly with an annual yield of 261.78%.
- Dividend Growth: Since 2004, the dividend payout has decreased by 24.2%, from $0.41 to $0.31.
- Dividend Reliability: NXL has maintained or increased its dividend for 7 consecutive payments.
Company News
Nexalin Technology announced the issuance of U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia, providing intellectual property protection through 2042. The patent strengthens the company's competitive position in non-invasive deep-brain neurostimulatio...
Nexalin announced a peer-reviewed study published in BMC Psychiatry demonstrating that its DIFS 77.5 Hz high-gamma neurostimulation technology produced statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents. The pilot study of six patients showed clinical improvements with measurable changes in...
Nexalin Technology, a neurostimulation company, will participate in the 2025 Maxim Growth Summit, showcasing its non-invasive brain stimulation technology for mental health treatment.
Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, announced the closing of a $5.0 million public offering of its common stock.
Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeho...
